Lupin gets approval for Penicillamine Tablets USP

01 Dec 2020 Evaluate

Lupin has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.

Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1580.45 -0.10 (-0.01%)
24-Apr-2024 15:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1484.55
Dr. Reddys Lab 5951.05
Cipla 1398.55
Zydus Lifesciences 935.00
Lupin 1580.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.